Search
ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines. The new company, Vaxxilon, aims to discover, develop, and commercialize synthetic carbohydrate vaccines. Vaxxilon has licensed exclusive rights to multiple preclinical vaccine candidates and additional technologies from Max-Planck Innovation GmbH, the technology transfer office of the Max Planck Society. Actelion is the principal investor and majority shareholder, having made a funding commitment of up to €30 million, to be released in tranches over a period of three to four years. Jean-Paul Clozel,
